专利检索 ap:("INTREXON CORP" OR "UNIV PITTBURGH OF THE COMMONWE") AND inv:"BRAUGHLER J MARK" 第 1 页

1.

发明公开
ENGINEERED DENDRITIC CELLS AND USES FOR THE TREATMENT OF CANCER 有权
标题翻译：技术手册DENDRITISCHE ZELLEN UND VERWENDUNGEN ZUR KREBSBEHANDLUNG

公开(公告)号：EP2207874A4

公开(公告)日：2010-11-10

申请号：EP08836827

申请日：2008-10-08

申请人： INTREXON CORP , UNIV PITTBURGH OF THE COMMONWE

发明人： BRAUGHLER J MARK , KUMAR PRASANNA , STORKUS WALTER J , OKADA HIDEHO

IPC分类号： C12N5/00 , C12N5/02 , C12N5/0784 , C12N15/00

CPC分类号： A61K35/15 , A61K31/00 , A61K31/166 , A61K31/4245 , A61K38/00 , A61K45/06 , C07K14/5434 , C07K2319/715 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2510/00 , C12N2710/10343 , C12N2830/002 , C12N2840/203 , G01N33/6866 , G01N2333/57 , G01N2800/52 , A61K2300/00

摘要： This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL- 12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

摘要翻译： 本发明提供治疗领域。最具体地，本发明提供了在激活配体存在下，在基因表达调节系统控制下有条件地表达白细胞介素-12（IL-12）的体外工程化树突状细胞的方法，以及用于包括人在内的动物的治疗目的。